Methods and compounds for treating cancer

Patent metadata

Field	Value
Publication number	US-10765654-B2
Application number	US-201214233301-A
Country	US
Kind code	B2
Filing date	Jul 19, 2012
Priority date	Jul 19, 2011
Publication date	Sep 8, 2020
Grant date	Sep 8, 2020

Abstract

The invention includes, in part, methods and compounds for treating cancer including, but not limited to gliomas, melanomas, and neuroblastomas. In some embodiments of the invention, a glyceryltriacetate compound is administered to a subject in an amount effective to treat or prevent a cancer in the subject.

First claim

What is claimed is:

1. A method for treating a cancer, the method comprising administering to a subject in need of treatment of a cancer, a glyceryltriacetate (GTA) compound in a therapeutically effective amount to treat the cancer, wherein the cancer is a glioma or a neuroblastoma.

2. The method of claim 1 , wherein treating the cancer comprises decreasing cancer stem cell proliferation in the subject.

3. The method of claim 1 , wherein treating the cancer comprises enhancing the cytosolic-nuclear shuttling of aspartoacylase (ASPA) and/or acetyl-CoA synthetase 1 (AceCS1).

4. The method of claim 1 , wherein the GTA compound is administered to the subject orally, intragastrically, or is administered into a surgical incision, opening, or cavity in the subject.

5. The method of claim 1 , further comprising administering one or more additional cancer-therapeutic agents to the subject.

6. The method of claim 5 , wherein the one or more additional cancer-therapeutic agents is temozolomide, bevacizumab, bis-chloroethylnitrosourea (BCNU), Lomustine, procarbazine, or vincristine.

7. The method of claim 5 , wherein the GTA compound and the one or more additional cancer chemotherapeutic agent are administered as a combination drug therapy.

8. The method of claim 1 , further comprising administering to the subject a surgical treatment to remove or reduce the cancer in the subject.

9. The method of claim 1 , wherein the GTA compound is administered to the subject in a pharmaceutical composition.

10. The method of claim 1 , wherein the subject does not have Canavan disease.

11. The method of claim 1 , wherein the subject is a human.

Assignees

• Jaworski Diane M
• Univ Of Vermont And State Agricultural College

Inventors

• Jaworski Diane M

Classifications

• A61K31/22 Primary

  of acyclic acids, e.g. pravastatin · CPC title

• A61K31/475

  having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375) · CPC title

• A61K31/175

  having the group [IMAGE cpc-sch-A61K-0950.gif] , >N—C(O)—N=N— or[IMAGE cpc-sch-A61K-0951.gif] , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof · CPC title

• A61K31/166

  having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title